Soft Gel Estradiol Capsule Minimizing Vaginal Discharge
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vulvovaginal atrophy (VVA) and female sexual dysfunction associated with estrogen deficiency, such as vaginal dryness and pain during sexual activity, face challenges including compliance issues due to the form of estradiol administration, which often results in irritation and increased vaginal discharge.
Innovation Solution
A soft gel vaginal pharmaceutical composition containing solubilized estradiol with a medium chain oil as a solubilizing agent, specifically caprylic/capric triglyceride, and a non-ionic surfactant like PEG-6 palmitostearate, encapsulated in a soft gelatin capsule, providing improved safety, efficacy, and patient compliance by minimizing discharge and irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional estradiol formulations are used for vaginal administration, then therapeutic effect is achieved, but patient compliance deteriorates due to irritation and increased vaginal discharge
Solution Approach 1:
The patent changes the physical and chemical parameters of the estradiol formulation by using solubilized estradiol in medium chain oils (such as caprylic/capric triglyceride) instead of conventional formulations. This parameter change reduces vaginal irritation and discharge while maintaining therapeutic efficacy, thereby improving patient compliance without sacrificing treatment effectiveness.
Solution Approach 2:
The invention employs composite material composition by combining estradiol with specific solubilizing agents (medium chain oils) and surfactants. This composite formulation approach creates a synergistic effect that enhances drug solubility and bioavailability while minimizing adverse local effects, resolving the contradiction between maintaining therapeutic effect and improving patient comfort/compliance.
2Object-affected harmful factors
If estradiol is administered vaginally to treat VVA, then symptoms are relieved, but vaginal irritation and discharge increase
Solution Approach 1:
The patent introduces medium chain oils (caprylic/capric triglyceride) and surfactants as intermediary substances that facilitate the delivery of estradiol to vaginal tissue. These intermediaries improve drug solubility and distribution while being gentler on vaginal mucosa compared to conventional formulations, thus reducing irritation and discharge while maintaining symptom relief.
Solution Approach 2:
By changing the formulation parameters from conventional estradiol to solubilized estradiol in medium chain oils, the patent modifies the interaction between the drug and vaginal tissue. This parameter change reduces the harmful effects (irritation and discharge) while preserving the beneficial therapeutic effects on VVA symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively delivers estradiol, reducing symptoms of VVA and female sexual dysfunction by maintaining therapeutic estradiol levels in the vagina, minimizing vaginal discharge, and improving patient compliance and safety profiles compared to existing treatments.
Implementation Method 1
a soft gel vaginal pharmaceutical composition containing solubilized estradiol with a medium chain oil as a solubilizing agent
Implementation Method 2
a non-ionic surfactant like PEG-6 palmitostearate
Data Source
AI summary
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).